Decision on IPR:
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
US Patent
|
Respondent
|
Status
|
|
IPR2016-00408
&
IPR2016-00409
|
12/29/2015
|
07/07/2016
|
Boehringer Ingelheim GmbH
|
8,889,135
|
AbbVie Biotechnology Ltd.
|
Final Written Decision – Jul 6, 2017
(Claims 1-5 are unpatentable)
|
The ’135 patent, titled “Methods of Administering Anti-TNFα Antibodies,” issued on November 18, 2014. The ’135 patent discloses methods of treating rheumatoid arthritis (“RA”) with a human anti-tumor necrosis factor α (“TNFα”) antibody.
Leave a Reply